Granules India’s Gagillapur facility located at Hyderabad in state of Telangana, has successfully completed US Food and Drug Administration (USFDA) inspection without any observations. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).
The company has recently received approval from USFDA for anti-inflammatory drug Ibuprofen tablets in the US market. The regulator has approved Abbreviated New Drug Application (ANDA) for Ibuprofen tablets USP, 200 mg (OTC) filed by the pharma major.
Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
